Impact of intra‐tumoral immunity on predicting response and survival after neoadjuvant cisplatin‐based chemotherapy in patients with muscle invasive bladder cancer

Documenti analoghi

• Efficacy and safety of dose‐dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle‐invasive bladder cancer
  di: Yuto Hattori, et al.
  Pubblicazione: (2024)
• Editorial Comment to “Efficacy and safety of dose‐dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle‐invasive bladder cancer”
  di: Eiji Kikuchi, et al.
  Pubblicazione: (2024)
• Muscle invasive bladder cancer treated with gemcitabine plus cisplatin as neoadjuvant chemotherapy during the second trimester of pregnancy
  di: Takeshi Sasaki, et al.
  Pubblicazione: (2025)
• Assessing risk of lymph node invasion in complete responders to neoadjuvant chemotherapy for muscle‐invasive bladder cancer
  di: Rocco Simone Flammia, et al.
  Pubblicazione: (2024)
• Effectiveness of dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine‐based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle‐invasive bladder cancer cases—Single‐center study in Japan
  di: Yozo Mitsui, et al.
  Pubblicazione: (2024)